Literature DB >> 1620653

Effects of CCK antagonists on CCK-induced suppression of locomotor activity in mice.

Y Hirosue1, A Inui, M Miura, M Nakajima, M Okita, N Himori, S Baba, M Kasuga.   

Abstract

Sulfated cholecystokinin octapeptide (CCK-8) was administered either intraperitoneally or into the cerebral ventricle of fully conscious mice, and locomotor activity was quantified. CCK-8 administered by either route suppressed locomotor activity. Subcutaneously administered selective CCK-A receptor antagonist, L-364,718 (1 mg/kg), reversed the inhibitory effect of centrally as well as peripherally administered CCK-8, but the selective CCK-B receptor antagonist, L-365,260 (1 mg/kg), did not. These results demonstrate that centrally as well as peripherally administered CCK-8 suppresses locomotor activity in mice through an interaction with CCK-A, but not CCK-B, receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1620653     DOI: 10.1016/0196-9781(92)90156-w

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  3 in total

1.  TMEM16B determines cholecystokinin sensitivity of intestinal vagal afferents of nodose neurons.

Authors:  Runping Wang; Yongjun Lu; Michael Z Cicha; Madhu V Singh; Christopher J Benson; Christopher J Madden; Mark W Chapleau; François M Abboud
Journal:  JCI Insight       Date:  2019-03-07

2.  Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist.

Authors:  M Poncelet; M Arnone; M Heaulme; N Gonalons; C Gueudet; V Santucci; O Thurneyssen; P Keane; D Gully; G Le Fur
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

Review 3.  Heterogeneity of Hypocretin/Orexin Neurons.

Authors:  Dana Sagi; Luis de Lecea; Lior Appelbaum
Journal:  Front Neurol Neurosci       Date:  2021-05-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.